Variable | Data |
---|---|
n | 234 |
Follow-up period, years, median (range) | 4.9 (2–11) |
Age, years, median (range) | 70 (46–86) |
MMSE score, mean ± SD | 24 ± 5 |
Female sex | 145 (62) |
Coresidency status | |
Cohabiting (female/male) | 99 (68)/79 (89) |
Living alone (female/male) | 46 (32)/10 (11) |
Education (years) | |
≤7 | 114 (49) |
8–12 | 71 (30) |
≥13 | 49 (21) |
CSF biomarkersa according to baseline AD stage, mean ± SD | |
t-tau, ng/L | MCI 723 ± 354, dementia 780 ± 558 |
p-tau, ng/L | MCI 102 ± 43, dementia 102 ± 48 |
Aβ42, ng/L | MCI 351 ± 114, dementia 374 ± 124 |
All three biomarkers normala | 5 (2) |
Low Aβ42, normal t-tau and p-tau | 21 (9) |
Low Aβ42, high t-tau or p-tau | 48 (21) |
Normal Aβ42, high t-tau and/or p-tau | 29 (12) |
All three biomarkers pathological | 131 (56) |
Baseline AD stage, n (%); MMSE score, mean (SD) | |
MCI | 134 (57); 26 ± 3 |
Mild dementia | 85 (36); 22 ± 4 |
Moderate dementia | 15 (7); 15 ± 6 |
NHP during follow-up | 112 (48) |
Males/females | 34 (38)/78 (54) |
MCI/dementia stage at baseline | 54 (40)/58 (58) |
Conversion to moderate dementia, n = 219 | 149 (68) |
From MCI at baseline | 83/134 (62) |
From mild dementia at baseline | 66/86 (77) |
Rapid cognitive declineb | 57 (24) |
MCI | 22 (16) |
Mild to moderate dementia | 35 (35) |
Death during follow-up | 83 (35) |
Death in severe dementia during follow-up | 46 (20) |
MCI | 19 (14) |
Mild to moderate dementia | 27 (27) |